Discontinuation report MYLAN-CIMETIDINE
Report ID | 16206 |
Drug Identification Number | 02227452 |
Brand name | MYLAN-CIMETIDINE |
Common or Proper name | CIMETIDINE |
Company Name | MYLAN PHARMACEUTICALS ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | CIMETIDINE |
Strength(s) | 400MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 100BT, 500BT |
ATC code | A02BA |
ATC description | DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | |
Actual discontinuation date | 2017-09-07 |
Remaining supply date | 2017-09-07 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | The last lot expires on 30-Apr-2018. |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
Company contact information | Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2017-07-18 | English | Compare |
v2 | 2017-07-18 | French | Compare |
v3 | 2017-07-18 | English | Compare |
v4 | 2017-07-18 | French | Compare |
v5 | 2017-09-08 | English | Compare |
v6 | 2017-09-08 | French | Compare |
Showing 1 to 6 of 6